May 5th, 2025 1st Quarter 2025 Financial Results & Corporate Update This Slide Presentation Includes Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech's expected revenues and net profit/(loss) related to sales of BioNTech's COVID-19 vaccine, referred to as COMIRNATY where approved for use under full or conditional marketing auth ...

BioNTech (BNTX) Q1 2025 Earnings Call May 05, 2025 08:00 AM ET Speaker0 Welcome to BioNTech's First Quarter twenty twenty five Earnings Call. I would like to hand the call over to Michael Horowitz, Director of Investor Relations. Please go ahead. Speaker1 Thank you. Good morning and good afternoon. Thank you for joining BioNTech's First Quarter twenty twenty five Earnings Call. As a reminder, the slides we will be using during this call and the corresponding press release we issued this morning can be found ...

Phase 1b/2a trial designed to evaluate the safety and feasibility of IFx-Hu2.0 in combination with Keytruda® when administered via Interventional Radiology (IR) in patients with deep- seated tumors without associated cutaneous tumorsTAMPA, Fla., May 5, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced the initiation of its Phase 1b/2a trial of ...

Core Insights - IO Biotech is advancing novel immune-modulatory therapeutic cancer vaccines, with a focus on reshaping the tumor microenvironment and enhancing T cell activation [1][2][3] Company Overview - IO Biotech is a clinical-stage biopharmaceutical company based in Copenhagen, Denmark, with a US headquarters in New York, specializing in off-the-shelf therapeutic cancer vaccines [3] - The company is developing its lead investigational cancer vaccine candidate, Cylembio® (IO102-IO103), which has received Breakthrough Therapy Designation from the FDA for advanced melanoma treatment [3] Scientific Contributions - Dr. Mads Hald Andersen, a co-founder of IO Biotech, presented at the 2025 AACR Annual Meeting, discussing advancements in cancer vaccine research and the dual mechanism of action of IO102-IO103 [1][2] - The vaccine targets both tumor cells and immune-suppressive cells, potentially reprogramming the tumor microenvironment to be more immune-permissive [2] Research and Development - The educational session at AACR highlighted key developments in RNA-based and immune-modulatory vaccines, showcasing the latest innovations in cancer immunotherapy [1][2] - IO Biotech's T-win® platform is designed to activate T cells against both tumor and immune-suppressive cells, representing a novel approach in cancer vaccine development [3]

TAMPA, Fla., April 8, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that an abstract highlighting Kineta Inc.'s novel KVA12123 antibody and an abstract from Moffitt Cancer Center scientists examining the mechanisms of Company's IFx-Hu2.0 therapy in advanced melanoma have been selected for poster presentation at the American Association for Cancer Research ...

Proven 20-year career in drug discovery and development track record leading to 12 pre-clinical/clinical candidates and 7 investigational new drug / clinical trial applicationsExtensive knowledge in the biochemistry and pharmacology of the Delta Opioid Receptor (DOR), the primary target in TuHURA's Antibody Drug Conjugate (ADC) and Antibody Peptide Conjugate (APC) technology platformInventor of first-in-class spirocyclic DOR agonists as potential analgesics; clinical- stage products licensed to PfizerLed th ...

For more details visit: www.aacr.org/meeting/aacr-annual-meeting-2025/abstracts. About IN8bio IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-100, is focused on acute myeloid leukemia evaluating haplo-matched allogeneic ...

Company Overview - Compugen Ltd. is a clinical-stage cancer immunotherapy company specializing in computational target discovery [3] - The company utilizes its predictive computational discovery platform, UnigenTM, to identify new drug targets and biological pathways for cancer immunotherapies [3] - Compugen has two proprietary product candidates in Phase 1 development: COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT for solid tumors [3] Upcoming Events - Compugen will participate in several virtual investor conferences in April 2025, including: - H.C. Wainwright 2nd Annual AI Based Drug Discovery & Development Conference on April 2, 2025, with a fireside chat at 9:30 am ET [1] - 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, with a fireside chat at 8:00 am ET [2] - Stifel's 2025 Virtual Targeted Oncology Forum on April 9, 2025, with a fireside chat at 12:00 pm ET [2] - Live webcasts of the fireside chats will be available on Compugen's Investor Relations website, with replays accessible after the events [2] Product Development - Rilvegostomig, a PD-1/TIGIT bispecific antibody, is in Phase 3 development by AstraZeneca under a license agreement [3] - GS-0321 (previously COM503), an anti-IL-18 binding protein antibody, is in Phase 1 development and licensed to Gilead [3] - The company has a pipeline of early-stage immuno-oncology programs aimed at enhancing anti-cancer immunity [3]